Orna Therapeutics / Lilly
Orna develops circular RNA in vivo cell therapies, including CD19-directed ORN-252 for B-cell-driven autoimmune diseases. Lilly completed the acquisition in 2026; its Q3 filing identifies ORN-252 as Phase 1 at acquisition. ReNAgade was acquired by Orna in 2024 and is not counted separately.
Corporate information
- Company entity
- Orna Therapeutics / Lilly
- Headquarters / principal office
- Watertown, Massachusetts, USASelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2019 (company-reported) ↗
- Ownership / capital status
- AcquiredNot verified
- Official corporate reference
- https://lilly.gcs-web.com/news-releases/news-release-details/lilly-acquire-orna-therapeutics-advance-cell-therapies ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Orna develops circular RNA in vivo cell therapies, including CD19-directed ORN-252 for B-cell-driven autoimmune diseases. Lilly completed the acquisition in 2026; its Q3 filing identifies ORN-252 as Phase 1 at acquisition. ReNAgade was acquired by Orna in 2024 and is not counted separately.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Orna Therapeutics / Lilly — official page checked November 4, 2026
- Orna Therapeutics / Lilly — supporting primary disclosure
- Orna Therapeutics / Lilly — supporting primary disclosure
- Founding / incorporation disclosure — scope stated in field